CurrentUnitedHealthcarePolicy CS064NJ.Q

Intensity Modulated Radiation Therapy Nj Cs

UnitedHealthcare medical policy (New Jersey only) defining coverage criteria for intensity-modulated radiation therapy (IMRT) for individuals aged 19 and older (policy applies to NJ; IMRT for <19 covered without further review). It lists proven/medically necessary indications, conditional exception criteria, unproven applications, documentation requirements, coding guidance, and supporting evidence.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity Modulated Radiation Therapy Nj Cs

Policy CodePolicy CS064NJ.Q

Change TypeMultiple revisions (additions, removals, and wording changes)

Effective DateMay 1, 2026

Next Review Date

Key ActionEnsure patient medical records include history, physical exam, and diagnostic test results that fully support medical necessity and make them available upon request.

SourceLink

POLICY UPDATE CHANGES

Revised list of conditions for which IMRT for definitive therapy for the primary site is proven and medically necessary, including additions and rewording for breast cancer criteria.

Added indications: hepatocellular carcinoma unresectable; Hodgkin lymphoma; intrahepatic cholangiocarcinoma unresectable; rectal cancer when treatment involves inguinal lymph nodes; small cell lung cancer limited stage; soft tissue sarcoma retroperitoneal/intra-abdominal; Stage I-II NSCLC undergoing hypofractionated RT up to 10 fractions.

Replaced language regarding hippocampal-avoidance whole brain radiation therapy up to 10 fractions to indicate it is 'considered proven and medically necessary' when criteria are met.

Removed statement that compensator based beam modulation treatment is proven and medically necessary when done in combination with an IMRT indication listed as proven.

Included billing notation instructing when to use 77407 vs 77412 and documentation requirements for 77412.

Added CPT codes 77407 and 77412 to applicable codes.

Added language clarifying medical records documentation may be required to assess clinical criteria and listing required documentation elements.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

MultipleProven Indications Listed

1Unproven Indications

NJGeographic Scope

>=19Age Applicability

2New CPT codes added

5CPT/HCPCS removed

Coverage Summary

UnitedHealthcare (New Jersey) Medical Policy CS064NJ.Q (effective May 1, 2026) defines coverage for intensity‑modulated radiation therapy (IMRT) for individuals aged 19 years and older in New Jersey, and notes IMRT for individuals <19 is covered without further review. The policy lists multiple indications for which IMRT is proven and medically necessary for definitive therapy of the primary site (examples include anus/anal canal, breast meeting listed criteria, CNS tumors, cervical, endometrial, esophageal, head and neck, unresectable hepatocellular carcinoma, intrahepatic cholangiocarcinoma, Hodgkin lymphoma, mediastinal tumors, specified NSCLC stages, pancreatic, prostate, rectal with inguinal node involvement, limited‑stage SCLC, retroperitoneal/intra‑abdominal soft tissue sarcoma, and vulvar cancer). Case‑by‑case exceptions are permitted when non‑IMRT techniques would meaningfully increase normal tissue toxicity on plan comparison or when prior irradiation requires sculpting of cumulative dose to avoid exceeding normal tissue tolerances. The policy also identifies one application as unproven and not medically necessary (IMRT used in conjunction with proton beam therapy). Coding and documentation highlights include added CPT codes 77407 and 77412, removed legacy codes, and explicit record and plan documentation requirements to support medical necessity.

Medical-Necessity Criteria

Proven and Medically Necessary - Definitive Therapy for Primary Site

IMRT is considered proven and medically necessary for definitive therapy of the primary site for the following conditions:

ALL of the following

Anus/anal canal cancer
Breast criteria
- When the left-sided internal mammary nodes are being treated
- Accelerated partial-breast irradiation of up to five fractions
Central nervous system tumors (primary or benign), including the brain, brainstem, and spinal cord
Cervical cancer
Endometrial cancer
Esophageal cancer
Head and neck cancers, including lymphoma and solitary plasmacytomas, when treatment includes the following areas: pharynx (nasopharynx, oropharynx, and hypopharynx), larynx, salivary glands, oral cavity (includes the tongue), nasal cavity, and paranasal sinuses
Hepatocellular carcinoma, unresectable
Intrahepatic cholangiocarcinoma, unresectable
Hodgkin lymphoma
Mediastinal tumors (e.g., lymphomas, thyroid, thymomas, tracheal cancer)
NSCLC criteria
- Stage I to II undergoing hypofractionated radiation therapy up to 10 fractions
- Stage III, undergoing chemoradiation therapy
Pancreatic cancer
Prostate cancer
Rectal cancer when treatment involves inguinal lymph nodes
Small cell lung cancer, limited stage
Soft tissue sarcoma, retroperitoneal/intra-abdominal location
Vulvar cancer

Hippocampal-Avoidance Whole-Brain Radiation Therapy (Proven and Medically Necessary)

Considered proven and medically necessary when ALL of the following are met:

HA-WBRT eligibility

Brain metastasis
Performance status: Eastern Cooperative Oncology Group performance status of ≤ 2 or Karnofsky performance status of ≥ 70ECOG ≤ 2 or KPS ≥ 70
Performance status threshold required
Prognosis of 4 months or greater≥ 4 months
Prognosis threshold required

IMRT Considered Medically Necessary (Case-by-Case Exceptions)

IMRT may be considered medically necessary for conditions not defined above when at least ONE of the following is present:

Case-by-case exceptions

Plan-comparison demonstration: Use of clinically appropriate radiation dose and a non-IMRT technique would increase the probability of clinically meaningful normal tissue toxicity as specified by RTOG or QUANTEC guidelines, demonstrated on a comparison of IMRT and non-IMRT (e.g., 3D conformal) treatment plans
Provide plan comparison demonstrating increased normal tissue toxicity with non-IMRT
Prior irradiation sculpting: Same or immediately adjacent area has been previously irradiated and dose distribution must be sculpted to avoid exceeding cumulative tolerance dose of nearby normal tissue
Document prior radiation and need to sculpt cumulative dose

Unproven and Not Medically Necessary

The following is unproven and not medically necessary due to insufficient evidence:

Unproven: IMRT used in conjunction with proton beam radiation therapy

No clinical evidence supports combined IMRT and PBRT in a single plan.

Not Medically Necessary / Unproven

The policy explicitly states that the following is unproven and not medically necessary due to insufficient evidence: IMRT used in conjunction with proton beam radiation therapy. No other exclusions are listed in the unproven section.

Coding

Referenced CPT/Procedure Codes (for reference only)CPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan.
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed.
77407	Radiation treatment delivery; Level 2, single-isocenter (e.g., 3D or IMRT), photons, including imaging guidance, when performed.
77412	Radiation treatment delivery; Level 3, multiple isocenters with photon therapy or single-isocenter with active motion management, including imaging guidance, when performed.
77520	Proton treatment delivery; simple, without compensation.
77522	Proton treatment delivery; simple, with compensation.
77523	Proton treatment delivery; intermediate.
77525	Proton treatment delivery; complex.

Added CPT codesCPT

77407	radiation treatment delivery, intermediate (standard single-isocenter IMRT or VMAT)
77412	radiation treatment delivery, complex (multiple isocenters or single-isocenter with active motion-management techniques)

Removed CPT/HCPCS codesmixedNot Covered

77385	removed from applicable codes (previously IMRT related)
77386	removed from applicable codes (previously IMRT related)
G6015	removed from applicable codes
G6016	removed from applicable codes
G6017	removed from applicable codes

Billing guidance: standard single‑isocenter IMRT or VMAT should be billed under CPT 77407, while CPT 77412 is for complex deliveries (multiple isocenters or single‑isocenter with active motion management); when 77412 is reported, documentation must clearly justify why Level 3 (77412) is appropriate versus Level 2 (77407).

Provider Actions & Documentation Requirements

Documentation Required

Medical record documentation requirement

The patient's medical record must contain documentation that fully supports the medical necessity for the requested IMRT service. History, physical examination, and results of pertinent diagnostic tests or procedures must corroborate the indication and be maintained in the medical record and made available upon request.

Required elements include: relevant medical history, focused physical exam, pathology/imaging reports, staging information (if applicable), prior radiation records and cumulative dose when re-irradiation is considered, and treatment planning comparisons when an exception is requested.
For hippocampal-avoidance whole-brain radiation therapy (HA-WBRT): document absence of metastasis within 5 mm of either hippocampus, estimated survival ≥ 4 months, and performance status (ECOG ≤ 2 or KPS ≥ 70).
When billing CPT 77412, documentation must justify Level 3 delivery (e.g., multiple isocenters, single-isocenter with active motion-management, or other complex delivery requirements) and include plan comparisons or intrafraction motion details.
Standard single-isocenter IMRT/VMAT should be billed using CPT 77407; reserve CPT 77412 for complex deliveries as described above.

Background & Evidence Summary

Background: IMRT is defined as an advanced, high‑precision external‑beam radiation therapy technique that modulates beam intensity to conform dose to the three‑dimensional tumor shape while sparing adjacent normal tissues. The policy notes IMRT is frequently used with image guidance (IGRT) to verify target positioning and adaptation during delivery, and that IMRT/VMAT is applied across many tumor types and in re‑irradiation scenarios where sculpting dose to avoid normal tissue tolerance is required.

Key Evidence & Guideline Highlights

Selected Evidence Items

Definitions

Term	Definition
Definitive Therapy
Radiation treatments for cancer with a curative intent (National Comprehensive Cancer Network, 2025; Landsteiner et al., 2023). The National Cancer Institute defines curative-intent therapy as a treatment designed to eliminate a disease or illness, aiming for a full recovery while maintaining satisfactory quality of life.
IMRT
Intensity Modulated Radiation Therapy, including VMAT; advanced conformal external beam radiotherapy technique to spare organs at risk
IGRT
Image Guided Radiation Therapy; imaging at time of delivery to verify target positioning
DIBH
Deep Inspiration Breath Hold; respiratory control technique to reduce cardiac and lung dose
IMRT
Intensity Modulated Radiation Therapy — advanced conformal external beam radiotherapy that modulates beam intensity to spare organs at risk.
HA-WBRT
Hippocampal-Avoidance Whole-Brain Radiation Therapy — WBRT delivered with techniques (eg IMRT) that spare hippocampal regions to preserve cognition.
HA-WBRT
Hippocampal-avoidance whole-brain radiation therapy using IMRT to spare the hippocampal neurogenic niche
BED
Biologically effective dose
IMRT
Intensity Modulated Radiation Therapy, an advanced form of external beam radiation that shapes dose distributions to spare normal tissues.
VMAT
Volumetric Modulated Arc Therapy, a type of IMRT delivered with rotating gantry arcs.
IGRT
Image Guided Radiation Therapy, daily imaging used to verify target localization.
BED10
Biologically effective dose calculated with alpha/beta = 10, used to compare fractionation regimens.
Definitive Therapy (updated)
Definition updated in the policy (specific updated wording not contained in this excerpt).

Revision History

2026-05-01policy_revision (latest)Latest

Policy revised and published (Effective May 1, 2026): replaced breast wording to 'breast cancer when any of the [listed] criteria are met'; added multiple proven/medically necessary indications (hepatocellular carcinoma unresectable; Hodgkin lymphoma; intrahepatic cholangiocarcinoma unresectable; rectal cancer when treating inguinal nodes; small cell lung cancer limited stage; soft tissue sarcoma retroperitoneal/intra‑abdominal; Stage I–II NSCLC hypofractionated up to 10 fractions); revised head & neck and mediastinal examples; changed hippocampal-avoidance WBRT wording to 'considered proven and medically necessary' when criteria met; removed compensator-based beam modulation statement; added CPT codes 77407 and 77412 and coding guidance; removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017; clarified medical records documentation requirements; updated Description/Clinical Evidence/References; archived prior policy version CS064NJ.P.

wording_change

Replaced wording 'breast cancer in the [listed] circumstances' with 'breast cancer when any of the [listed] criteria are met' to clarify selection logic for breast indications.

Policy Summary

PayerUnitedHealthcare

PolicyIntensity Modulated Radiation Therapy Nj Cs

Policy CodePolicy CS064NJ.Q

Change TypeMultiple revisions (additions, removals, and wording changes)

Effective DateMay 1, 2026

Next Review Date

Key ActionEnsure patient medical records include history, physical exam, and diagnostic test results that fully support medical necessity and make them available upon request.

SourceLink

On This Page

Absence of leptomeningeal disease

no leptomeningeal disease

Documentation Required

Comparison of treatment plans for exceptions

For case-by-case requests where IMRT is being considered solely to reduce normal tissue toxicity compared with a non-IMRT technique, a direct comparison of treatment plans is required to demonstrate the clinical benefit.

Provide dose–volume histograms and comparative plans (e.g., IMRT/VMAT vs 3D conformal) showing predicted normal tissue dose reductions that would be clinically meaningful per QUANTEC or relevant guideline thresholds.

Documentation Required

When billing 77412 justify level 3 delivery

When reporting CPT 77412 (Level 3 delivery), document why Level 3 is appropriate rather than Level 2. Examples that may justify Level 3 include complex delivery circumstances.

77412 — justify Level 3 delivery with documentation such as multiple isocenters, single-isocenter with active motion-management (e.g., gating, real-time tracking), or mixed electron/photon fields.
77407 — use for standard single-isocenter IMRT/VMAT (Level 2) unless documentation supports Level 3.

Billing Rule

Use of CPT 77407 for standard single-isocenter IMRT/VMAT

Standard single-isocenter IMRT or VMAT deliveries should be billed with CPT code 77407.

77407 — Radiation treatment delivery; Level 2 (single-isocenter IMRT/VMAT). Bill 77407 for routine single-isocenter photon IMRT/VMAT treatments including routine image guidance when performed.

Billing Rule

Use of CPT 77412 for complex delivery

Use CPT 77412 for complex delivery only when clinical documentation supports Level 3 delivery requirements.

77412 — Radiation treatment delivery; Level 3. When billed, attach documentation justifying complexity (multiple isocenters, active motion management, total skin electrons, or mixed fields) and include treatment planning and motion-management details as applicable.

Documentation Required

HA-WBRT eligibility documentation

For hippocampal-avoidance whole-brain radiotherapy (HA-WBRT) eligibility, the record must clearly document specific clinical and imaging findings supporting the approach.

Absence of metastases within 5 mm of either hippocampus on contemporary brain MRI.
Estimated survival ≥ 4 months.
Performance status: ECOG ≤ 2 or Karnofsky Performance Status ≥ 70.

Documentation Required

Image guidance recommendation for advanced techniques

Advanced IMRT/VMAT techniques should be accompanied by appropriate image guidance and motion-management documentation to support accurate delivery and organ-at-risk protection.

Document use of image-guided radiation therapy (IGRT) modalities (kV/MV imaging, cone-beam CT) and intrafraction motion management (4D imaging, breath-hold/gating, fiducial tracking) when used.
For moving targets (e.g., lung, liver), include 4DCT-based planning, gating/breath-hold technique details, or tracking strategy, and document relevant organ-at-risk constraints and liver function assessments when applicable.
Follow guideline-recommended IMRT techniques (e.g., MLC use, dose–volume histogram reporting per target and critical structures) and archive planning data (plans, DVHs, and imaging) in the medical record.

Prior Authorization

Coverage determined by federal/state/contractual requirements

Benefit coverage for IMRT is determined by applicable federal, state, and contractual requirements. UnitedHealthcare may request medical records to verify that services meet those requirements.

Coverage is subject to federal/state/contractual rules and applicable law.
Medical records may be requested to determine if the member meets policy clinical criteria.

Note

Provider Actions — additional notes

This policy is provided as clinical guidance. It does not replace clinical judgment and is not a guarantee of coverage. UnitedHealthcare may use third-party clinical decision support tools (e.g., InterQual) and retains the right to request additional records or to apply benefit terms specific to the member's contract.

Use this policy as guidance only; individualized clinical decisions remain under the treating clinician's responsibility.
UnitedHealthcare may reference third-party tools (such as InterQual) during review and may request supporting documentation.
Archive reference: previous policy version(s) and revision history are maintained in the policy record for audit and historical comparison.

Additional provider actions in the brief cover guideline-concordant technique recommendations, fractionation and dose-escalation documentation, heart dose consideration for NSCLC (document heart dose constraints and consider cardiac sparing when appropriate), and that UnitedHealthcare may use third-party tools like InterQual during prior authorization or medical necessity review.

added_indications

Added proven/medically necessary indications: hepatocellular carcinoma (unresectable); Hodgkin lymphoma; intrahepatic cholangiocarcinoma (unresectable); rectal cancer when treatment involves inguinal lymph nodes; small cell lung cancer (limited stage); soft tissue sarcoma in retroperitoneal/intra‑abdominal location; Stage I–II NSCLC undergoing hypofractionated RT up to 10 fractions.

revised_language

Changed phrasing for hippocampal-avoidance whole-brain radiation therapy up to 10 fractions from 'proven and medically necessary' to 'considered proven and medically necessary' when criteria are met.

removed_statement

Removed statement that compensator-based beam modulation treatment is proven and medically necessary when combined with an IMRT indication listed as proven.

coding_added

Added CPT codes 77407 and 77412 to applicable codes and included coding clarification: 77407 for standard single‑isocenter IMRT/VMAT (Level 2); 77412 for complex delivery (Level 3) with documentation requirement to justify Level 3 vs Level 2.

coding_removed

Removed CPT/HCPCS codes 77385, 77386, G6015, G6016, and G6017 from applicable codes.

documentation_clarified

Added/clarified medical records documentation requirements: patient record must contain relevant history, physical exam, and diagnostic test results supporting medical necessity; documentation must be legible and made available upon request.

supporting_sections_updated

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

archival

Archived previous policy version CS064NJ.P.